How does CAR-T therapy actually work against autoimmune disease?
CAR-T therapy is a living drug: a patient's own T cells are genetically engineered to recognize and destroy a specific target — in this case, CD19, a protein found on most B cells. In autoimmune diseases like lupus or myositis, rogue B cells produce self-attacking antibodies. By wiping out nearly all CD19-positive B cells and their antibody-producing offspring (plasmablasts), CAR-T cells essentially reset the immune system. After the B cells are gone, the body regenerates a fresh, naïve B-cell population that is no longer primed to attack itself [1][4][9]. This is fundamentally different from standard immunosuppressants, which just dampen the whole immune system without fixing the underlying problem.
The depth of this reset is key. In the largest case series to date — 15 patients across three autoimmune diseases — the average duration of B-cell depletion was about 112 days (roughly 4 months), after which B cells returned but the autoimmune attack did not [1]. All 15 patients stopped all immunosuppressive drugs and remained in remission for a median follow-up of 15 months (range 4 to 29 months) [1]. This suggests the therapy doesn't just suppress symptoms; it eliminates the memory of autoimmunity.
Which autoimmune diseases have been treated, and how well does it work?
The strongest evidence so far comes from systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis. In the 15-patient NEJM case series, every single patient with SLE met strict remission criteria (DORIS remission), every myositis patient achieved a major clinical response, and every sclerosis patient saw a drop in their disease activity score [1]. A separate case report on antisynthetase syndrome (a severe form of myositis with lung involvement) showed that 8 months after CAR-T infusion, muscle inflammation on MRI had completely resolved, lung function improved, and anti-Jo-1 antibody levels fell [3]. The therapy has also been tested in two patients with progressive multiple sclerosis, where it proved safe and reduced antibody production inside the spinal fluid — a notoriously difficult site to treat [5].
Across the studies here, the pattern is consistent: CAR-T therapy works best in B-cell-driven autoimmune diseases. The list now includes SLE, myositis, systemic sclerosis, antisynthetase syndrome, myasthenia gravis, neuromyelitis optica, and multiple sclerosis [4][6][8]. In every case, the goal is the same — deep B-cell depletion leading to an immune reset — and early results show drug-free remission lasting at least 1–2 years [1][4]. No therapy has yet been tested in large randomized trials, but the consistency across multiple disease types and independent centers is encouraging.
What are the risks, and what still needs to be figured out?
The main short-term risk is cytokine release syndrome (CRS) — a flu-like inflammatory reaction that occurs when CAR-T cells activate. In the 15-patient study, 10 patients had mild (grade 1) CRS, one had grade 2, and one had a temporary neurological side effect (ICANS) [1]. One patient developed pneumonia requiring hospitalization [1]. These rates are lower than those seen in cancer patients, likely because autoimmune patients are generally healthier and not heavily pre-treated with chemotherapy. No deaths or lasting toxicities were reported in any of these studies [1][3][5].
Longer-term, the big unknowns are durability and access. Will remissions last beyond 2–3 years? We don't know yet — follow-up is still short [1][4]. The therapy is also extremely complex and expensive: it requires harvesting a patient's cells, genetically engineering them in a lab, and giving chemotherapy beforehand (lymphodepletion) [1][2]. Researchers are already working on simpler approaches, such as injecting lipid nanoparticles that reprogram T cells inside the body, eliminating the need for the lab step [9]. But for now, CAR-T remains a last-resort option for patients with severe, refractory autoimmune disease who have failed multiple other treatments [4][7].
About These Sources
This answer is built on 9 peer-reviewed studies — published from 2023 to 2026, 8 from 2024 or later, 9 in Q1 journals, collectively cited 1,637 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 45 papers retrieved from a database of over 500 million.
Sources used in this answer
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
In a case series of 15 patients with SLE, myositis, or systemic sclerosis, all achieved drug-free remission after a single CD19 CAR-T infusion, with median follow-up of 15 months and only mild CRS in most patients.
CAR T Cells and T-Cell Therapies for Cancer
Reviews FDA-approved CAR-T products for six hematologic cancers, noting no CAR-T is yet approved for solid tumors or autoimmune diseases, but T-cell therapies are expanding.
CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome
A single patient with refractory antisynthetase syndrome (myositis + lung disease) achieved complete resolution of muscle inflammation on MRI and normalized muscle enzymes 8 months after CD19 CAR-T therapy.
Advancements and challenges in CAR T cell therapy in autoimmune diseases
Comprehensive review of CAR-T in B-cell-mediated autoimmune diseases, including SLE, myositis, sclerosis, neuromyelitis optica, myasthenia gravis, and MS, emphasizing the concept of immune reset.
CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis
First report of CD19 CAR-T in two progressive MS patients; therapy was safe, CAR-T cells entered the spinal fluid without causing neurotoxicity, and intrathecal antibody production decreased.
Chimeric antigen receptor T cell therapy for autoimmune disease
Reviews CAR-T design considerations for autoimmunity, including chimeric autoantibody receptors (CAARs) for selective B-cell depletion and CAR-Tregs for immune modulation.
Chimeric antigen receptor T cell therapy for autoimmune diseases
Reviews clinical outcomes of CAR-T in SLE, sclerosis, myasthenia gravis, and rheumatoid arthritis, highlighting durable immune reprogramming but noting barriers like toxicity and antigen escape.
CAR T cell therapy: Autoimmune neurological uses and neurotoxicities.
Reviews CAR-T for autoimmune neurological conditions (myasthenia gravis, MS, CIDP, stiff person syndrome) and notes that neurotoxicities like ICANS remain a limitation but are manageable.
In vivo CAR T cell generation to treat cancer and autoimmune disease
Describes a novel in vivo CAR-T generation method using lipid nanoparticles that reprogram T cells inside the body, achieving B-cell depletion in monkeys without ex vivo manufacturing.